Investment Landscape: Neurodegeneration

Overview

Overview

The neurodegenerative disease investment landscape represents one of the largest and most active therapeutic areas in biopharmaceuticals. With an aging global population and no disease-modifying therapies approved for most conditions, the unmet medical need drives substantial investment across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and other disorders. The convergence of advances in disease biology, biomarker development, and novel therapeutic modalities has created unprecedented investment opportunities in this space.

Market Size and Growth

The global neurodegenerative disease therapeutics market was valued at approximately $35-40 billion in 2024, with projections suggesting growth to $65+ billion by 2032[@grand2024]. Alzheimer's disease accounts for the largest share, followed by Parkinson's disease and other dementias. The market growth is driven by several factors:

Key Market Drivers

• Aging population demographics: Global populations are aging rapidly, with the number of individuals aged 65 and older projected to reach 1.6 billion by 2050[@united2022]
• Increasing prevalence: Alzheimer's disease affects over 6 million Americans alone, with projections reaching 12 million by 2050[@alzheimers2024]
• Novel therapeutic approvals: The approvals of [lecanemab](/entities/lecanemab) (Leqembi) and [donanemab](/entities/donanemab) have validated amyloid-targeting approaches, spurring additional investment[@van2023]
• Advances in biomarkers: PET imaging, blood-based biomarkers, and genetic testing enable better patient selection and monitoring[@hansson2024]
• Diverse therapeutic modalities: Growth in antibodies, gene therapy, RNA therapeutics, and small molecule approaches

Investment by Therapeutic Area

Alzheimer's Disease

Alzheimer's disease represents the largest segment of neurodegeneration investment, with major pharmaceutical companies including Biogen, Eisai, Eli Lilly, and Roche having invested billions in clinical development[@cummings2024]. The field has evolved from symptomatic treatments to disease-modifying therapies targeting [amyloid-beta](/proteins/amyloid-beta), tau, and emerging targets like [APOE](/proteins/apoe) and synaptic proteins.

Key investment areas include:

• Amyloid-targeting antibodies (lecanemab, donanemab, gantenerumab)
• Tau-targeting therapies (anti-tau antibodies, small molecule inhibitors)
• Neuroinflammation modulation
• Synaptic protection and repair
• Metabolic and mitochondrial targets

Parkinson's Disease

Parkinson's disease investment has grown substantially, with focus on [alpha-synuclein](/proteins/alpha-synuclein) targeting therapies, LRRK2 inhibitors, and gene therapies[@tolosa2024]. Companies including AbbVie, Roche, and numerous biotech companies have active development programs.

Key investment themes include:

• Alpha-synuclein aggregation inhibitors and antibodies
• LRRK2 inhibitors (multiple companies in clinical development)
• GBA and lysosomal function modulators
• Gene therapy approaches (AAV-based delivery)
• Neuroprotection and neurorestoration

Amyotrophic Lateral Sclerosis (ALS)

ALS investment has accelerated following recent approvals and improved understanding of disease biology[@hardiman2017]. Focus includes SOD1 targeting, [C9orf72](/entities/c9orf72) approaches, and neuroprotection strategies. The approval of tofersen for SOD1-ALS has validated the genetic stratification approach.

Other Neurodegenerative Disorders

Investment in rare neurodegenerative conditions continues to grow, including:

• [Frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD)
• [Progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP)
• [Corticobasal degeneration](/diseases/corticobasal-degeneration) (CBD)
• [Multiple system atrophy](/diseases/multiple-system-atrophy) (MSA)
• [Huntington's disease](/diseases/huntington-disease)

Funding Sources and Investment Trends

Pharmaceutical Company Investment

Large pharmaceutical companies maintain robust neurodegeneration pipelines through internal discovery, academic collaborations, and strategic acquisitions. Major players include:

• Eli Lilly (Alzheimer's, Parkinson's)
• Biogen/Eisai (Alzheimer's)
• Roche/Genentech (Alzheimer's, Parkinson's)
• AbbVie (Parkinson's)
• Novartis (ALS, Alzheimer's)
• Pfizer (Multiple indications)

Venture Capital Investment

VC investment in neurodegeneration startups has increased significantly[@evaluate2023]. Notable deals include:

• Biohaven (ALZ, Parkinson's)
• Prothelia (ALS, muscular dystrophy)
• Caris Life Sciences (biomarkers)
• Athira Pharma (Alzheimer's)
• multiple preclinical and clinical stage companies

Government and Foundation Funding

NIH funding for neurodegenerative disease research exceeds $3 billion annually[@nih2024], with substantial support from foundations including the Alzheimer's Association, Michael J. Fox Foundation for Parkinson's Research, and ALS Association.

Key Investment Themes

1. Disease Modification Over Symptomatic Relief

Investment has shifted decisively toward disease-modifying therapies that address underlying pathology rather than just symptoms. This represents a fundamental change from the symptomatic treatment paradigm that dominated for decades.

2. Precision Medicine Approaches

Genetic stratification and biomarker-driven development enable more targeted therapies. Key genetic targets include:

• [APP](/entities/app-protein) and [PSEN1](/entities/psen1)/PSEN2 (Alzheimer's)
• LRRK2, GBA, SNCA (Parkinson's)
• SOD1, C9orf72, FUS (ALS)
• [MAPT](/proteins/tau) (FTD)

3. Combination Therapies

Recognizing the complexity of neurodegenerative diseases, investment in combination approaches targeting multiple pathways simultaneously has grown. Examples include amyloid + tau targeting, or neuroinflammation + protein aggregation.

4. Early Intervention

Prevention trials in pre-symptomatic populations have become a major investment theme, enabled by biomarker screening. The DIAN-TU, A4, and similar studies have established frameworks for secondary prevention trials.

5. Biomarker Development

Investment in biomarkers for diagnosis, patient selection, and treatment response monitoring has expanded significantly. Blood-based biomarkers represent a particularly active area of development[@blennow2024]. The FDA has approved several biomarker-based diagnostic tests, enabling more precise patient selection.

6. Novel Modalities

Beyond traditional small molecules and antibodies, investment has expanded into new therapeutic modalities:

• Gene therapy: AAV-based delivery for precision targeting (e.g., LRRK2 antisense, PARK2 gene therapy)
• RNA therapeutics: Antisense oligonucleotides (ASOs) for genetic forms of AD, PD, and ALS
• Cell therapy: iPSC-derived neurons for replacement strategies
• Protacs/molecular glues: Targeted protein degradation for undruggable targets
• Microbiome modulation: Fecal transplant and probiotic approaches

Investment by Phase

| Phase | AD Trials | PD Trials | ALS Trials | FTD Trials |
|-------|-----------|-----------|-------------|------------|
| Phase 1 | 480 | 337 | 138 | 34 |
| Phase 2 | 636 | 485 | 216 | 46 |
| Phase 3 | 321 | 253 | 71 | 12 |
| Active Total | 1,208 | 1,061 | 434 | 124 |

Deal Activity and M&A

The neurodegeneration space has seen significant M&A activity:

| Year | Company | Deal | Value |
|------|---------|------|-------|
| 2020 | Biogen | Eisai partnership (lecanemab) | $1B+ |
| 2021 | Eli Lilly | Avid Radiopharmaceuticals acquisition | $500M |
| 2022 | Roche | Prothelia licensing | $100M+ |
| 2023 | Novartis | Versanis Bio acquisition | $1.9B |
| 2024 | Eli Lilly | Protoqor acquisition | $200M+ |
| 2024 | AbbVie | Cerevel acquisition | $8.7B |
| 2025 | Roche | CarbX acquisition | $500M+ |

Recent Notable Deals (2024-2025)

• AbbVie/Cerevel ($8.7B): AbbVie's acquisition of Cerevel Therapeutics provided broad neuroscience pipeline including Parkinson's and Alzheimer's programs
• Novo Nordisk/Metaphore: Partnership for GLP-1 based neurodegeneration approaches
• Biogen/Fahrenheit Therapeutics: Acquisition of novel tau program
• UCB/Mission Therapeutics: Strategic partnership for ubiquitin-proteasome targeting

2025-2026 Investment Developments

Recent market developments continue to show strong interest in neurodegeneration:

• NIH funding increase: February 2026 saw a $100 million increase for Alzheimer's and dementia research signed into law, plus $41.5 million for public health efforts[@alzfunding2026]
• Market growth projections: Global neurodegenerative disease therapeutics market expected to reach $60B+ by 2030, driven by aging demographics and new therapeutic approvals
• GLP-1 receptor agonists: Novo Nordisk and Eli Lilly expanding into neurodegeneration with GLP-1 based approaches showing promise in AD and PD
• Gene therapy maturation: AAV gene therapy for neurological disorders advancing with multiple Phase 1/2 programs reporting positive data
• AI-driven drug discovery: Increasing investment in computational approaches for novel target identification and drug design
• Biomarker expansion: Blood-based biomarkers (p-tau217, p-tau181, α-synuclein seed assay) enabling earlier diagnosis and better trial design

2026 Investment Developments

• Pfizer returns to neuroscience: After prior pullback, Pfizer re-entered neurodegeneration with new Alzheimer's program
• Novo Nordisk neurodegeneration pipeline: Ozempic/Wegovy (semaglutide) showing protective effects in AD and PD observational studies
• AI drug discovery platforms: Recursion, Exscientia, and Insilico Medicine advancing AI-discovered candidates into Phase 1/2
• RNA therapeutics expansion: Ionis, Biogen, and Wave Life Sciences advancing ASO programs for AD, PD, and ALS
• Tau PET imaging approval: New tau PET tracers approved enabling better patient selection for anti-tau trials
• Regulatory momentum: FDA granted multiple breakthrough therapy designations for neurodegeneration programs

Challenges and Risk Factors

Despite significant investment, the neurodegeneration field faces challenges:

• High clinical trial failure rates: Historically, over 99% of Alzheimer's drug candidates have failed
• Complex disease biology: Multiple interconnected pathways complicates target selection
• Heterogeneous patient populations: Disease presentation varies significantly
• Regulatory considerations: FDA has shown flexibility but standards remain high
• Reimbursement challenges: Pricing and access for novel therapies
• Long development timelines: Typical development spans 10+ years

Future Outlook

The neurodegeneration investment landscape continues to evolve positively. With multiple disease-modifying therapies now approved or in late-stage development, the field has achieved critical milestones that de-risk future investments. Key areas of continued interest include:

• Next-generation amyloid antibodies with improved efficacy
• Tau-targeted therapies
• Alpha-synuclein modulators for Parkinson's
• Gene therapy platforms
• RNA therapeutics
• Repositioned drugs with novel mechanisms

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References